Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06147843
Recruiting Not applicable

French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis

NCT06147843 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Limoges
Phase
Not applicable
Started
2024-09-17
Last updated
2026-08-06

Condition(s) studied

Amyotrophic Lateral Sclerosis

Investigational drug(s) / intervention(s)

Blood sample

Blood sample: Blood sample will be taken to identify Genomic, metabolomic, metabolic, neurofilaments, and inflammation markers associated to weight loss

Study summary

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. Studies have shown the importance of weight loss at the time of diagnosis and during the progression of the disease. However, the pathophysiological mechanisms behind weight loss remain unknown. Identifying these mechanisms could make it possible to propose an effective therapeutic strategy against weight loss for ALS patients, which could improve their survival and quality of life. In this context, the investigators are proposing an innovative multidisciplinary project aimed at structuring a large Franco-German cohort to identify the markers associated with weight loss in ALS.

Participants will undergo high quality standard care for ALS patients. In addition, participants will be asked to respond different questionnaires and blood samples will be taken for analysis to identify biological markers.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Incident cases included at the time of diagnosis with a definite, probable, probable laboratory-supported, or possible ALS according to El Escorial revised criteria and Gold Coast criteria for early diagnosis. * Incident ALS cases identified and followed-up in the participant ALS \& Other Motor Neuron Diseases Referral Centres: seven in France and two in Germany. * Patients who signed the informed consent form. * Adults aged \>18 years old Exclusion Criteria: * Inability to understand the requirements of the protocol. * Cognitive inability to sign and comprehend the informed consent form. * Patients who will not accept Riluzole therapy during their follow-up.

Primary outcome measure(s)

  • Survival — every 6 month until 18 months of follow up
    Survival evaluated in month since diagnosis

Trial sites (9)

FacilityCityRegionStatus
CHU de Lille Lille France Recruiting
Limoges University Hospital Limoges France Recruiting
Hôpital de la Timone Marseille France Recruiting
Hôpital Gui Chauliac Montpellier France Recruiting
CHU de Nice Nice France Recruiting
Hôpital de la Pitié Salpêtrière Paris France Recruiting
CHU de Tours Tours France Recruiting
Klinik für Medizinische Hochschule Hannover Carl-Neuberg-Str. 1 Hanover Allemagne Not Yet Recruiting
Klinik für Neurologie, Universitäts- und Rehabilitationskliniken Ulm (RKU Ulm Allemagne Not Yet Recruiting

More University Hospital, Limoges trials in France

Prevention of Secondary Infections by Interferon Gamma in ICU-acquired Sustained Immune-suppression Recruiting
Effects of the COTID (Community Occupational Therapist in Dementia) Program and Usual Occupational Therapy Care on Recurrence of Falls at 12 Months in Elderly People With Neurocognitive Disorders Who Had Been Hospitalized for Falls, After Their Return Home Recruiting
INterest of the Negative Predictive Value of Integrons in the reduCtion of Large Broad-spectrum anTibiotics Consumption for Urinary Tract infectionS Starting soon
DELTA DESCRIBE: the French Collaborative Project Recruiting
Prospective Imaging Assessment of Perineo-pelvic Static's Evolution After Sexual Reassignment Surgery in MtF Transgender Patient, by Peno-scrotal Inversion Vaginoplasty Technique (TRANSPELV) Recruiting

Other trials for the same condition

Contribution of Diaphragmatic Ultrasound for Monitoring Diaphragmatic Function in Patients With Amyotrophic Lateral Sclerosis Recruiting
Anticipated Patient and Caregiver Burden Recruiting
ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach Active, not recruiting
Staging System in Amyotrophic Lateral Sclerosis Active, not recruiting
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06147843 on ClinicalTrials.gov ↗ ← All trials in France